Recent Articles

• 
  Global Business

  Eating to Lose Weight: Obesity Pill Wars

  The “oral obesity drug” race has begun. According to Reuters and other foreign media on the 2nd (local time), the US Food and Drug Administration (FDA) on the 1st approved Eli Lilly’s oral obesity treatment “Poundayo (orforglipron).” Following Novo Nordisk’s launch of oral Wegovy at the beginning of

  2026.04.03
• 
  AI Healthcare

  Holmes AI Selected for Nvidia Startup Support Program

  Medical AI platform specialist Holmes AI (홈즈AI) announced on the 2nd that it will join “NVIDIA Inception,” NVIDIA’s global startup support program.NVIDIA Inception is a program that discovers and nurtures startups with innovation in the fields of artificial intelligence (AI), data science, and high-

  2026.04.02
• 
  Medical / Clinical Case

  Celltrion Proves Zympentra Dose Increase Effective

  Celltrion Second Plant. Provided by Celltrion Celltrion announced on the 2nd that a paper containing the post-hoc analysis results from the global Phase 3 clinical trial of “Zympentra (Remsima SC),” the world’s only subcutaneous (SC) formulation of infliximab, has been published in the latest issue

  2026.04.02
• 
  Pharmaceutical R&D

  LG Chem to Develop Novel Cancer Drug, Licenses FMC-220

  LG Chem CI. Provided by LG Chem LG Chem is moving to develop an innovative anticancer drug targeting an unaddressed target by introducing a new drug candidate.LG Chem announced on the 1st that it has signed an exclusive global license agreement for development and commercialization of the anticancer

  2026.04.02
• 
  Biopharma

  Daewoong Pharma Launches Low-Dose Statin Combo Drug

  Daewoong Pharmaceutical headquarters. Courtesy of Daewoong Pharmaceutical Daewoong Pharmaceutical announced on the 1st that it has launched the dyslipidemia combination drug “BaroEzet Tablet” (pitavastatin/ezetimibe combination) and has begun full-scale sales. BaroEzet Tablet is a new low-dose combi

  2026.04.01
• 
  Medical / Drug Development

  SK Biopharm Seeks US FDA Nod for Liquid Cenobamate to Aid Patients With Swallowing Issues

  SK Biopharmaceuticals announced on the 1st that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an oral suspension formulation of cenobamate, its innovative anti-seizure medication for epilepsy, marketed in the United States under the brand name XCOPR

  2026.04.01
• 
  Global Business

  Samsung Biologics Completes Rockville Plant Acquisition

  Panoramic view of a biopharmaceutical manufacturing facility in Rockville, U.S. Provided by Samsung Biologics Samsung Biologics has completed the acquisition of a biopharmaceutical manufacturing facility located in Rockville, Maryland, in the United States. With this acquisition, the company has sec

  2026.04.01
• 
  Medical / Research

  Vets Propose Korean Standard for Small Dog Bile Duct Surgery

  The joint research team that has secured publication in JSAP with the development of a small-breed dog-tailored bile duct surgery technique. (From left) Veterinarians Myung Hyeon-uk, Eom Tae-heum, and Son Dong-joo Gallbladder mucocele and the resulting extrahepatic biliary obstruction (EHBO) are lif

  2026.04.01
• 
  Global Expansion

  From Songdo to World: Next-Gen Vaccine, Bio Push

  Panoramic view of SK bioscience’s Global R&PD Center in Songdo. Provided by SK bioscience SK bioscience is accelerating its mid- to long-term growth strategy based on global collaboration. In January, the company relocated its headquarters and research institute to the Songdo R&PD Center, establ

  2026.04.01
• 
  Biopharma

  AI-Driven Obesity Drugs Spur Next K-Bio Battle

  Getty Images Bank 《Domestic pharmaceutical and bio companies are demonstrating their research and development capabilities by continuously achieving results in new drug candidate discovery, clinical progress, and large-scale technology transfer deals. In particular, they are rapidly building R&D cap

  2026.04.01